Should I Buy ABBV? ABBV 2026 Analysis

Should You Buy AbbVie Inc (ABBV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

223.430

1 Day change

2.01%

52 Week Range

244.810

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: ABBV is extended into resistance (~227.8) with momentum strong but near-term upside capped without a fresh catalyst surprise.
Earnings are scheduled pre-market (QDEC 2025), and ABBV is priced for a solid quarter (street already expects strong YoY growth); risk/reward is not compelling right before the report.
Options positioning is bullish-leaning, but there is no Intellectia buy signal today, and recent Congress activity is net selling—together arguing against chasing at current levels.
Better risk/reward would appear on a pullback toward the pivot/support zone (~220.8).

Technical Analysis

Trend: Bullish (SMA_5 > SMA_20 > SMA_200), indicating an established uptrend.
Momentum: MACD histogram positive and expanding (0.976), supportive of continuation.
RSI(6): 66.3 (upper-neutral/near-overbought), suggesting limited near-term room before a cooling phase.
Key levels: Pivot 220.84 (important support); Resistance R1 227.80 then R2 232.10. Price at 225.78 is close to R1, implying less attractive chase entry.
Pattern-based forward bias: modest near-term weakness implied (next week model expectation slightly negative), with a better 1-month tilt positive.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/Call ratios skew bullish (more call interest and especially call volume vs puts).
Activity: Volume ~~in-line with 30-day average (~~99.6%), suggesting no unusual options rush yet.
Volatility: 30D IV 26.68 vs HV 23.67; IV percentile 62 (options moderately expensive), consistent with an earnings/event setup.

Technical Summary

Sell

Buy

Positive Catalysts

pre-market with consensus calling for strong growth (news cites ~23% EPS increase, ~8.7% revenue growth).

Neutral/Negative Catalysts

with RSI elevated—near-term pullback risk increases even in an uptrend.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $15.776B, +9.10% YoY (top-line growth remains solid).
Profitability: Net income $176M (-88.65% YoY) and EPS $0.10 (-88.64% YoY) show a sharp earnings deterioration versus last year (suggests heavy expenses/one-offs or margin pressure that the market will focus on).
Gross margin: 71.75%, +1.24% YoY (core gross profitability held up despite bottom-line pressure).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings have drifted more mixed/neutral at current price levels (Citi Neutral PT cut to $230; UBS initiated Neutral $240; Wolfe downgraded to Peer Perform) alongside several bullish voices (Berenberg Buy $275; HSBC Buy $265; Morgan Stanley Overweight $269; Scotiabank Outperform $280).
Price targets: Broad range roughly $230–$280, with the more cautious firms implying limited upside from current ~$226.
Wall Street pros: Strong immunology franchise momentum (Skyrizi/Rinvoq), resilient cash flow/dividend, and potential undervalued pipeline readouts.
Wall Street cons: Stock viewed as fairly priced by several firms; competitive dynamics for key drugs in 2026–2027 could compress future growth expectations.

22 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218 USD and a high forecast of 289 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

7 Hold

0 Sell

Moderate Buy

Current: 219.020

Low

218

Averages

253.26

High

289

Current: 219.020

Low

218

Averages

253.26

High

289

UBS

Neutral

downgrade

$240 -> $230

AI Analysis

2026-02-05

New

Reason

UBS

Price Target

$240 -> $230

AI Analysis

2026-02-05

New

downgrade

Neutral

Reason

UBS lowered the firm's price target on AbbVie to $230 from $240 and keeps a Neutral rating on the shares.

Evercore ISI

Gavin Clark-Gartner

Outperform

downgrade

$232 -> $228

2026-02-04

New

Reason

Evercore ISI

Gavin Clark-Gartner

Price Target

$232 -> $228

2026-02-04

New

downgrade

Outperform

Reason

Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on AbbVie to $228 from $232 and keeps an Outperform rating on the shares. Despite Tremfya clearly taking share, 2026 guidance/consensus still look beatable, same with 2027, the analyst tells investors in a research note. The firm also said that it is "worth noting" that the buyside has been above consensus for a while, and the margin beats look smaller. Evercore added that the real issue the stock is reflecting is the 2028+ growth, especially as more new entrants come online.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

ABBV Should I Buy

ABBV Should I Buy

Should You Buy AbbVie Inc (ABBV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch